BR0214932A - Prodrogas para d-prolinas - Google Patents
Prodrogas para d-prolinasInfo
- Publication number
- BR0214932A BR0214932A BR0214932-0A BR0214932A BR0214932A BR 0214932 A BR0214932 A BR 0214932A BR 0214932 A BR0214932 A BR 0214932A BR 0214932 A BR0214932 A BR 0214932A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- och
- hydroxy
- independently
- treatment
- Prior art date
Links
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 title 1
- 229930182820 D-proline Natural products 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 abstract 1
- 102100036202 Serum amyloid P-component Human genes 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- -1 benzyloxy, hydroxy Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"PRODROGAS PARA D-PROLINAS". A presente invenção refere-se aos compostos de fórmula (1) ou em que R^ 1^ e R^ 2^ são independentemente um do outro e significam alcóxi inferior, alquenilóxi inferior, benzilóxi, hidróxi, -OCH (CH~ 3~) OC (O)-alquila inferior ou OCH~ 2~C (O) N (R^ 3^) (R^ 4^), com a condição que somente um dentre R^ 1^ ou R^ 2^ pode ser hidróxi; R^ 3^e R^ 4^ são independentemente um do outro e significam hidrogênio, alquila inferior, alquenila inferior ou cicloalquila; ou R^ 1^ e R^ 2^ formam juntos com o átomo de carbono, ao qual eles são fixados, o grupo de ligação X, em que X é -O (CH~ 2~)n CH=CH (CH~ 2 )~ n~0- ou -O (CH~ 2~)~ m~O-; n é 1, 2 ou 3; e m é 4 - 8, assim como sais farmaceuticamente aceitáveis dos referidos compostos. Os compostos da presente invenção podem ser usados para o tratamento de doenças onde a depleção de componente P amilóide no soro tem um efeito benéfico, particularmente no tratamento ou prevenção de todas as formas de amiloidose central e sistêmica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01129793 | 2001-12-14 | ||
| PCT/EP2002/013827 WO2003051836A1 (en) | 2001-12-14 | 2002-12-06 | Prodrugs to d-prolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214932A true BR0214932A (pt) | 2004-11-30 |
Family
ID=8179542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214932-0A BR0214932A (pt) | 2001-12-14 | 2002-12-06 | Prodrogas para d-prolinas |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6903129B2 (pt) |
| EP (2) | EP1458680A1 (pt) |
| JP (1) | JP4192100B2 (pt) |
| KR (1) | KR100678785B1 (pt) |
| CN (1) | CN100368397C (pt) |
| AR (1) | AR038010A1 (pt) |
| AU (1) | AU2002361982B2 (pt) |
| BR (1) | BR0214932A (pt) |
| CA (1) | CA2470037C (pt) |
| GT (1) | GT200200275A (pt) |
| HR (1) | HRP20040494A2 (pt) |
| HU (1) | HUP0402600A3 (pt) |
| IL (2) | IL162158A0 (pt) |
| MX (1) | MXPA04005693A (pt) |
| MY (1) | MY129431A (pt) |
| NO (1) | NO20042979L (pt) |
| NZ (1) | NZ533188A (pt) |
| PA (1) | PA8561201A1 (pt) |
| PE (1) | PE20030764A1 (pt) |
| PL (1) | PL370803A1 (pt) |
| RU (1) | RU2305679C2 (pt) |
| TW (1) | TWI225400B (pt) |
| UY (1) | UY27584A1 (pt) |
| WO (1) | WO2003051836A1 (pt) |
| ZA (1) | ZA200404546B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| RU2530601C2 (ru) * | 2012-10-05 | 2014-10-10 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Ингибитор образования цинк-зависимых димеров бета-амилоида |
| GB201407506D0 (en) * | 2014-04-29 | 2014-06-11 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
| DK0915088T3 (da) | 1997-10-31 | 2003-01-27 | Hoffmann La Roche | D-prolinderivater |
-
2002
- 2002-12-02 US US10/307,699 patent/US6903129B2/en not_active Expired - Lifetime
- 2002-12-06 HR HR20040494A patent/HRP20040494A2/hr not_active Application Discontinuation
- 2002-12-06 HU HU0402600A patent/HUP0402600A3/hu unknown
- 2002-12-06 AU AU2002361982A patent/AU2002361982B2/en not_active Ceased
- 2002-12-06 NZ NZ533188A patent/NZ533188A/en not_active IP Right Cessation
- 2002-12-06 CA CA2470037A patent/CA2470037C/en not_active Expired - Fee Related
- 2002-12-06 WO PCT/EP2002/013827 patent/WO2003051836A1/en not_active Ceased
- 2002-12-06 CN CNB028249348A patent/CN100368397C/zh not_active Expired - Fee Related
- 2002-12-06 EP EP02796578A patent/EP1458680A1/en not_active Withdrawn
- 2002-12-06 RU RU2004121783/04A patent/RU2305679C2/ru not_active IP Right Cessation
- 2002-12-06 PL PL02370803A patent/PL370803A1/xx not_active Application Discontinuation
- 2002-12-06 EP EP06020711A patent/EP1743884A1/en not_active Withdrawn
- 2002-12-06 IL IL16215802A patent/IL162158A0/xx unknown
- 2002-12-06 KR KR1020047009036A patent/KR100678785B1/ko not_active Expired - Fee Related
- 2002-12-06 MX MXPA04005693A patent/MXPA04005693A/es active IP Right Grant
- 2002-12-06 JP JP2003552723A patent/JP4192100B2/ja not_active Expired - Fee Related
- 2002-12-06 BR BR0214932-0A patent/BR0214932A/pt not_active Application Discontinuation
- 2002-12-10 PE PE2002001184A patent/PE20030764A1/es not_active Application Discontinuation
- 2002-12-11 TW TW091135829A patent/TWI225400B/zh not_active IP Right Cessation
- 2002-12-11 PA PA20028561201A patent/PA8561201A1/es unknown
- 2002-12-12 AR ARP020104818A patent/AR038010A1/es unknown
- 2002-12-13 GT GT200200275A patent/GT200200275A/es unknown
- 2002-12-13 UY UY27584A patent/UY27584A1/es not_active Application Discontinuation
- 2002-12-13 MY MYPI20024679A patent/MY129431A/en unknown
-
2004
- 2004-05-24 IL IL162158A patent/IL162158A/en not_active IP Right Cessation
- 2004-06-08 ZA ZA200404546A patent/ZA200404546B/en unknown
- 2004-07-13 NO NO20042979A patent/NO20042979L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308495A (pt) | Composto, formulação farmacêutica, métodos para ativar receptores de 5-ht1f, para inibir o extravasamento de proteìna neuronal, para tratar ou prevenir enxaqueca em um mamìfero e para preparar um composto, uso de um composto, e, processo para preparar um composto | |
| NL350075I2 (pt) | ||
| BR0112475A (pt) | N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina | |
| BG104998A (en) | Isothiazole derivatives useful as anticancer agents | |
| PA8480201A1 (es) | Derivados de quinilin-2-ona utiles como agentes contra el cancer | |
| BR9806413A (pt) | Composto e uso do mesmo | |
| EP2400847A4 (en) | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOINE COMPOUNDS | |
| PT1254138E (pt) | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf | |
| CY1107853T1 (el) | Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων | |
| ATE533492T1 (de) | Behandlung oder prävention von hypertensiven erkrankungen in der schwangerschaft oder von wachstumsverzögerung des foeten | |
| BR0214932A (pt) | Prodrogas para d-prolinas | |
| ATE435223T1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| BRPI0409465A (pt) | derivados de carboxamida como agentes antidiabéticos | |
| BR0210293A (pt) | Uma preparação farmacêutica aquosa de cilostazol para utilização parenteral | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| DE69713273D1 (de) | Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms | |
| BR0312798A (pt) | Derivados de isotiazol úteis como agentes anticancerìgenos | |
| BR0213465A (pt) | Compostos de 4-imidazolin-2-ona | |
| BRPI0413384A (pt) | inibidores da proteìna farnesil transferase como agentes antitumores | |
| BR0006299A (pt) | Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina | |
| DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
| DE60123117D1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
| BR0214606A (pt) | Processos para a preparação de derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal | |
| ATE509905T1 (de) | Benzamidderivate | |
| WO2003106656A3 (en) | SINGLE-DOMAIN COMPOUNDS ASSOCIATED WITH TDF AND THE LIKE THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |